BMI is a leading edge, privately-held vaccine design and development company located in Frederick, Maryland, USA. For the past several years, the Company has been devoted to developing its proprietary “Immune Refocusing Technology” or “IRT” related to the dampening or enhancement of pathogen epitopes to encourage a more effective natural immune response. Recently, the Company has developed a proprietary inactivation technology aimed at developing innovative vaccines for inadequately served global health needs. These recent efforts have included developing ultraIPV™.
Briefly, the target organisms are complexed with a manganese-decapeptide-phosphate (MDP) mixture and then exposed to UV light. A very quick, easy and reproducible process. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans.
The MDP-UV inactivation method is a platform technology. BMI and collaborators are applying the technology to the development of vaccines against additional important human pathogens, such as MRSA and Acinetobacter baumannii, two hard-to-treat bacteria that are resistant to multiple antibiotics.